<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> (programmed cell <z:hpo ids='HP_0011420'>death</z:hpo>) is an important regulatory mechanism in hematopoiesis, and is thought to be a principal mechanism of action of cytotoxic chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Proteins that modulate <z:mpath ids='MPATH_3'>apoptosis</z:mpath> include bcl-2, which inhibits <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and Fas (CD95, also known as <z:chebi fb="16" ids="53704">APO</z:chebi>-1), which induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in susceptible cells bound by Fas ligand (FasL) </plain></SENT>
<SENT sid="2" pm="."><plain>To characterize precisely the expression of these <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-regulatory proteins in <z:mpath ids='MPATH_458'>normal</z:mpath> and neoplastic hematopoiesis, the authors have performed multiparameter flow cytometric (FCM) analysis in a series of <z:mpath ids='MPATH_458'>normal</z:mpath> and abnormal marrow specimens </plain></SENT>
<SENT sid="3" pm="."><plain>Among <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoietic elements, bcl-2 expression was highest in myeloblasts (29 [+/- 9] x 10(3) molecules of equivalent soluble <z:chebi fb="1" ids="51217">fluorochrome</z:chebi> [MESF]), and lymphocytes (28[+/- 7] x 10(3) MESF) </plain></SENT>
<SENT sid="4" pm="."><plain>bcl-2 was essentially undetectable in granulocytes and nucleated red blood cells, whereas monocytes and B-cell precursors expressed intermediate levels of bcl-2 (11[+/- 4] x 10(3) and 7[+/- 1] x 10(3) MESF, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Fas expression increased with granulocytic and monocytic differentiation; myeloblasts expressed 8(+/- 2) x 10(3) MESF, whereas granulocytes (15 [+/- 2] x 10(3) MESF) and monocytes (28[+/- 5] x 10(3) MESF) displayed relatively greater intensity of staining for Fas </plain></SENT>
<SENT sid="6" pm="."><plain>Among lymphoid cells, Fas expression was <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>B cells expressed lower intensity Fas staining than both CD4+ and CD8+ T cells </plain></SENT>
<SENT sid="8" pm="."><plain>Myeloblasts in 30 cases of myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> studied for bcl-2 and/or Fas expression manifested variable levels of these molecules (range 9-105 x 10(3) MESF for bcl-2 and 3-33 x 10(3) MESF for Fas) </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, intraclonal <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of bcl-2 and Fas expression was seen in certain cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, which correlated with extent of differentiation </plain></SENT>
<SENT sid="10" pm="."><plain>Among 28 cases of B-precursor ALL studied for bcl-2 and/or Fas expression, bcl-2 ranged from 22 to 60 x 10(3) MESF (P &lt; .001 versus <z:mpath ids='MPATH_458'>normal</z:mpath> marrow B-cell precursors), and Fas varied between essentially undetectable levels and 6 x 10(3) MESF </plain></SENT>
<SENT sid="11" pm="."><plain>In summary, <z:mpath ids='MPATH_458'>normal</z:mpath> marrow subsets display characteristic levels of the <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-regulatory molecules, bcl-2 and Fas </plain></SENT>
<SENT sid="12" pm="."><plain>In hematopoietic <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, expression of bcl-2 and Fas varies among cases, and in some instances, within leukemic blast populations </plain></SENT>
<SENT sid="13" pm="."><plain>Further study is required to understand the potential significance of this <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> expression of bcl-2 and Fas in hematologic <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
</text></document>